Neurochips Enable Nanoscale Devices for High-Resolution In Vivo Neurotransmitter Sensing
The demand for new strategies to combat debilitating psychiatric and neurodegenerative diseases necessitates revolutionizing our approaches to investigate the connectivity and function of neural circuits. To elucidate how alterations in neuronal networks, which function at nanoscale synapses, contribute to brain-related disorders, it will be essential to monitor chemical neurotransmission in vivo at the length and timescales pertinent to intrinsically encoded information (Andrews, 2013) . Nonetheless, current approaches for sensing neurotransmitters are far removed from these scales needed to decode chemical information processing in neurocircuitry.
To address the challenges of designing ultra-small, fast, highly selective, and multiplexed biosensors, we are investigating aptamers, which have emerged as alternatives to antibodies for molecular recognition. Aptamers are synthetic single-stranded DNA or RNA sequences that fold into unique three-dimensional structures to effect specific interactions with binding targets. Yet despite their promise, the elucidation of these rare nucleotide sequences is impeded by difficulties associated with producing screening substrates having highly controlled surface chemistries and characteristics (Vaish et al, 2010) . Aptamers with picomolar to femtomolar dissociation constants exist but they are limited to sequences that recognize molecules significantly larger than neurotransmitters. To unleash the full potential of aptamers for in vivo neurotransmitter biosensing, we have invested a decade of research aimed at developing materials that enable high-affinity interactions between neurotransmitters tethered to optimized biospecific surfaces and nucleic acid libraries.
These substrates, termed 'neurochips', are fabricated so as to create enhanced environments for molecular recognition by controlling essential parameters and reducing nonspecific binding ( Figure 1 ). Neurochips selectively capture large biomolecule binding partners including antibodies, native G-protein-coupled receptors (Vaish et al, 2010) , and nucleic acid aptamers. At present, we are using neurochips to identify rare nucleotides isolated from combinatorial libraries consisting of hundreds of billions of candidate sequences based on relative affinities for small-molecule neurotransmitter targets. We have also developed micro-to nanoscale surface patterning techniques (Liao et al, 2012) and used high-throughput microfluidics (Liao et al, 2013) to create multiplexed neurotransmitter substrates. A significant advantage of multiplexed patterning is the capacity to capture and to sort different neurotransmitterspecific aptamers side-by-side while providing opportunities to determine and to compare in situ binding affinities.
The discovery of neurotransmitter aptamers will enable their functional integration into nanometer-diameter field-effect transistor (FET) nanowires, which will function as neurotransmitter recording elements (Figure 1 ). Devices patterned with aptamer-modified FETs will be used to carry out dynamic in vivo monitoring of neurotransmission with response times on the order of milliseconds (or faster) (Kim et al, 2015) . When combined with appropriate passivation to suppress biofouling, microsensors that detect dopamine with sub-second temporal resolution have been shown to function over months in vivo in rats and mice (Clark et al, 2010) . Thus, neurochips will enable the development of devices that will advance the understanding of the roles of small-molecule neurotransmitters in the complex landscape of brain interneuronal communication and dysfunction. Unraveling the emergent properties of integrated chemical neurotransmission associated with neural circuits using this approach will be advantageous for uncovering processes associated with cognition, emotion, and learning and memory.
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